GLPHubglpresearchhub.com
Read-only archive. GLP Research Hub is a static community record — nothing here is for sale, no account is needed, and no vote you cast is counted. Why?
Single comment threadYou are looking at one branch of reading MASH threads from 2024 and half of it aged badly — 43 comments in the full submission. View in context.
2.2k
c/survodutide·submitted 2 years ago by u/julia_mensa

reading MASH threads from 2024 and half of it aged badly

Questionbranch of 8 comments

Long-ish post, sorry. tl;dr at the bottom. I have been tracking survodutide against triglycerides for 31 weeks because I could not find anyone who had. The correlation is weaker than I expected, which is itself mildly interesting given how confidently people link the two in here. Caveats up front: one person, one…

Read the full submission and all 43 comments →

This branch

8 comments, started 2 years ago
u/dario_boateng25 points·2 years ago

Titration speed is a side-effect dial far more than an efficacy dial.

replysharereportpermalink
[removed]19 points·2 years ago

[removed by moderator]

replysharereportpermalink
u/lyophile_lou9 points·2 years ago

the GLP-1/glucagon dual is hepatic fat, different from GIP/GLP-1

replysharereportpermalink
u/deleted_my_history21 points·2 years ago

Inter-lab variance on this kind of assay is routinely 1–2 points. Different column, different gradient, different integration.

replysharereportpermalink
u/sofia_ferreira31 points·2 years ago

This is correct. Do not generalise from tirzepatide.

replysharereportpermalink
u/patient_labslip_log25 points·2 years ago·edited

Hepatic fat or MASH or what?

replysharereportpermalink
u/sofia_ferreira8 points·2 years ago·edited

the safety profile is not just tirzepatide amplified

replysharereportpermalink
u/farid_kuipers4 points·2 years ago

the safety profile is not just tirzepatide amplified

Adding to this: MASH is doing more work than the comment implies.

replysharereportpermalink

← back to the whole thread

About c/survodutide

Survodutide-specific discussion: glucagon-receptor co-agonism, the hepatic fat and MASH resolution data, and how the side-effect profile compares with GIP-based dual agonism. Small community, high signal.

12kmembers
62submissions
Feb 2024created
submissions / month, last year
Sponsored

PeptideMeter Analytics

Independent testing plus vendor-level trend data. Community-funded, unaffiliated.

peptidemeter.com
More in c/survodutide
c/survodutide rules
  1. Glucagon co-agonism has a distinct safety story. Do not generalise from tirzepatide.
  2. MASH claims need the trial and the biopsy endpoint.
  3. Not approved. Descriptive posts only.
  4. Independent community. Nobody here sells anything, and anyone who tries is banned.
  5. Not medical advice. Describe what you did; never prescribe to a stranger.
  6. Claims need evidence. Batch numbers, dated screenshots, independent test reports, or a citation.
  7. No referral links, discount codes or affiliate URLs. Permanent ban, no appeal.
  8. No contact handles, wallet addresses or tracking numbers — they identify people.
  9. Be recognisably decent. Disagree hard, insult nobody.
Full rules and how they are enforced →
Moderators
u/incretin_ivyu/liver_enzyme_lizu/trialwatch_theo
Volunteers. Unpaid, unaffiliated, and reachable through modmail only.
Before you read on

Several compounds discussed on GLP Research Hub are sold for research use only and are not approved for human use anywhere. Nothing here is medical advice and none of it is written by your clinician. If a post reads like an instruction, treat it as a description of what one stranger did.

Full disclaimer →